CN102361557A - 制备阿格列汀的方法 - Google Patents

制备阿格列汀的方法 Download PDF

Info

Publication number
CN102361557A
CN102361557A CN2010800136497A CN201080013649A CN102361557A CN 102361557 A CN102361557 A CN 102361557A CN 2010800136497 A CN2010800136497 A CN 2010800136497A CN 201080013649 A CN201080013649 A CN 201080013649A CN 102361557 A CN102361557 A CN 102361557A
Authority
CN
China
Prior art keywords
compound
formula
described method
group
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800136497A
Other languages
English (en)
Chinese (zh)
Inventor
E·马罗姆
M·米垂斯基
S·如博诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mapi Pharma Ltd
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Publication of CN102361557A publication Critical patent/CN102361557A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2010800136497A 2009-03-26 2010-03-25 制备阿格列汀的方法 Pending CN102361557A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16348109P 2009-03-26 2009-03-26
US61/163,481 2009-03-26
PCT/IL2010/000260 WO2010109468A1 (en) 2009-03-26 2010-03-25 Process for the preparation of alogliptin

Publications (1)

Publication Number Publication Date
CN102361557A true CN102361557A (zh) 2012-02-22

Family

ID=42780220

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800136497A Pending CN102361557A (zh) 2009-03-26 2010-03-25 制备阿格列汀的方法

Country Status (9)

Country Link
US (1) US8841447B2 (enExample)
EP (1) EP2410855B1 (enExample)
JP (1) JP2012521411A (enExample)
CN (1) CN102361557A (enExample)
AU (1) AU2010228902A1 (enExample)
BR (1) BRPI1013561A8 (enExample)
CA (1) CA2755561A1 (enExample)
MX (1) MX2011010079A (enExample)
WO (1) WO2010109468A1 (enExample)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102942556A (zh) * 2012-12-04 2013-02-27 成都天翼医药科技有限公司 一种苯甲酸阿格列汀的制备工艺
CN103193762A (zh) * 2013-03-29 2013-07-10 山东罗欣药业股份有限公司 苯甲酸阿格列汀的制备方法
CN103910710A (zh) * 2012-12-29 2014-07-09 广东东阳光药业有限公司 阿格列汀新晶型及其制备方法
CN104086527A (zh) * 2014-07-03 2014-10-08 湖南欧亚生物有限公司 一种苯甲酸阿格列汀的合成方法
CN104447685A (zh) * 2013-09-23 2015-03-25 上海天慈生物谷生物工程有限公司 一种阿洛利汀的制备方法
WO2014188334A3 (en) * 2013-05-24 2015-06-25 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of alogliptin
CN104961726A (zh) * 2015-06-19 2015-10-07 浙江永宁药业股份有限公司 一种曲格列汀的制备方法
CN105085475A (zh) * 2014-05-09 2015-11-25 上海科胜药物研发有限公司 一种合成阿格列汀中间体的方法
CN105315256A (zh) * 2014-07-07 2016-02-10 广州朗圣药业有限公司 一种适合工业化的高纯度琥珀酸曲格列汀的制备方法
CN105777709A (zh) * 2014-12-22 2016-07-20 上海医药工业研究院 阿格列汀的制备工艺
CN105801490A (zh) * 2016-05-05 2016-07-27 青岛辰达生物科技有限公司 一种制备阿格列汀中间体的方法
CN105837557A (zh) * 2016-05-05 2016-08-10 青岛辰达生物科技有限公司 一种用于治疗ii型糖尿病的阿格列汀的制备方法
CN105968091A (zh) * 2016-05-05 2016-09-28 青岛辰达生物科技有限公司 一种制备治疗ii型糖尿病药物阿格列汀的方法
CN107311940A (zh) * 2017-07-26 2017-11-03 中国人民解放军第三军医大学 一种嘧啶二酮类化合物的制备方法
CN109232443A (zh) * 2018-10-29 2019-01-18 中国药科大学 嘧啶酮衍生物、其制备方法及医药用途
CN110128401A (zh) * 2018-02-02 2019-08-16 新发药业有限公司 一种苯甲酸阿格列汀的简便制备方法
CN114057685A (zh) * 2020-07-31 2022-02-18 西安新通药物研究有限公司 一种高收率苯甲酸阿格列汀的制备方法
CN114105889A (zh) * 2021-12-16 2022-03-01 山东创新药物研发有限公司 一种dpp-iv抑制剂关键中间体的制备方法及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130317251A1 (en) 2011-02-10 2013-11-28 Solvay Sa Process for the manufacture of fluoromethoxymalonic acid derivatives
WO2013046229A1 (en) * 2011-09-26 2013-04-04 Hetero Research Foundation Novel salts of alogliptin
WO2015092739A1 (en) * 2013-12-19 2015-06-25 Mylan Laboratories Ltd. Process for preparation of alogliptin
WO2016178246A1 (en) 2015-05-04 2016-11-10 Indoco Remedies Limited Process for the preparation of alogliptin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1086818A (zh) * 1992-08-10 1994-05-18 贝林格尔·英格海姆公司 不对称取代的黄嘌呤
CN1926128A (zh) * 2004-03-15 2007-03-07 武田药品工业株式会社 二肽基肽酶抑制剂
CN101006086A (zh) * 2004-06-11 2007-07-25 日本烟草产业株式会社 用于治疗癌症的5－氨基－2,4,7－三氧代－3,4,7,8－四氢－2H－吡啶并[2,3－d]嘧啶衍生物和相关化合物
WO2007150011A2 (en) * 2006-06-23 2007-12-27 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8031A (en) * 1851-04-08 Gkraih separator and ban
US2598936A (en) * 1950-04-13 1952-06-03 Searle & Co Disubstituted cyanoalkanoylureas and thioureas and methods for their production
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
DE4114238A1 (de) * 1991-04-26 1992-10-29 Zentralinstitut Fuer Organisch Neue substituierte 2,2 -pentamethylen-(delta)(pfeil hoch)3(pfeil hoch)-imidazolin-5-one bzw. 2,2 -pentamethylen-imidazolidin-5-one und verfahren zu deren herstellung
JPH08319288A (ja) * 1994-06-20 1996-12-03 Takeda Chem Ind Ltd 縮合イミダゾール誘導体、その製造法及び剤
US6066641A (en) * 1994-12-13 2000-05-23 Euro-Celtique S.A. Aryl thioxanthines
US6248746B1 (en) * 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
IL139884A0 (en) * 1998-05-26 2002-02-10 Natural Drug Sciences Llc N-substituted derivatives of 5-oximinobarbituric acid
WO2001029010A1 (en) * 1999-10-21 2001-04-26 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
BRPI0609317A2 (pt) * 2005-03-24 2010-03-16 Janssen Pharmaceutica Nv derivados de pirimidindiona como antagonistas de receptores de procineticina 2
CN102675221A (zh) * 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
TW200745080A (en) 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
GEP20125672B (en) 2007-07-19 2012-10-25 Takeda Pharmaceuticals Co ) solid composition containing alogliptin and metformin hydrochloride
TW201040175A (en) 2009-02-04 2010-11-16 Pfizer 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1086818A (zh) * 1992-08-10 1994-05-18 贝林格尔·英格海姆公司 不对称取代的黄嘌呤
CN1926128A (zh) * 2004-03-15 2007-03-07 武田药品工业株式会社 二肽基肽酶抑制剂
CN101006086A (zh) * 2004-06-11 2007-07-25 日本烟草产业株式会社 用于治疗癌症的5－氨基－2,4,7－三氧代－3,4,7,8－四氢－2H－吡啶并[2,3－d]嘧啶衍生物和相关化合物
WO2007150011A2 (en) * 2006-06-23 2007-12-27 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102942556A (zh) * 2012-12-04 2013-02-27 成都天翼医药科技有限公司 一种苯甲酸阿格列汀的制备工艺
CN103910710B (zh) * 2012-12-29 2017-06-16 乳源东阳光药业有限公司 阿格列汀新晶型及其制备方法
CN103910710A (zh) * 2012-12-29 2014-07-09 广东东阳光药业有限公司 阿格列汀新晶型及其制备方法
CN103193762A (zh) * 2013-03-29 2013-07-10 山东罗欣药业股份有限公司 苯甲酸阿格列汀的制备方法
CN103193762B (zh) * 2013-03-29 2015-07-29 山东罗欣药业集团股份有限公司 苯甲酸阿格列汀的制备方法
WO2014188334A3 (en) * 2013-05-24 2015-06-25 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of alogliptin
CN104447685A (zh) * 2013-09-23 2015-03-25 上海天慈生物谷生物工程有限公司 一种阿洛利汀的制备方法
CN105085475B (zh) * 2014-05-09 2019-05-21 上海科胜药物研发有限公司 一种合成阿格列汀中间体的方法
CN105085475A (zh) * 2014-05-09 2015-11-25 上海科胜药物研发有限公司 一种合成阿格列汀中间体的方法
CN104086527A (zh) * 2014-07-03 2014-10-08 湖南欧亚生物有限公司 一种苯甲酸阿格列汀的合成方法
CN105315256A (zh) * 2014-07-07 2016-02-10 广州朗圣药业有限公司 一种适合工业化的高纯度琥珀酸曲格列汀的制备方法
CN105315256B (zh) * 2014-07-07 2018-02-06 广州朗圣药业有限公司 一种适合工业化的高纯度琥珀酸曲格列汀的制备方法
CN105777709A (zh) * 2014-12-22 2016-07-20 上海医药工业研究院 阿格列汀的制备工艺
CN104961726A (zh) * 2015-06-19 2015-10-07 浙江永宁药业股份有限公司 一种曲格列汀的制备方法
CN105837557A (zh) * 2016-05-05 2016-08-10 青岛辰达生物科技有限公司 一种用于治疗ii型糖尿病的阿格列汀的制备方法
CN105968091A (zh) * 2016-05-05 2016-09-28 青岛辰达生物科技有限公司 一种制备治疗ii型糖尿病药物阿格列汀的方法
CN105801490A (zh) * 2016-05-05 2016-07-27 青岛辰达生物科技有限公司 一种制备阿格列汀中间体的方法
CN107311940A (zh) * 2017-07-26 2017-11-03 中国人民解放军第三军医大学 一种嘧啶二酮类化合物的制备方法
CN107311940B (zh) * 2017-07-26 2019-08-30 中国人民解放军第三军医大学 一种嘧啶二酮类化合物的制备方法
CN110128401A (zh) * 2018-02-02 2019-08-16 新发药业有限公司 一种苯甲酸阿格列汀的简便制备方法
CN110128401B (zh) * 2018-02-02 2020-04-28 新发药业有限公司 一种苯甲酸阿格列汀的简便制备方法
CN109232443A (zh) * 2018-10-29 2019-01-18 中国药科大学 嘧啶酮衍生物、其制备方法及医药用途
CN109232443B (zh) * 2018-10-29 2022-03-08 中国药科大学 嘧啶酮衍生物、其制备方法及医药用途
CN114057685A (zh) * 2020-07-31 2022-02-18 西安新通药物研究有限公司 一种高收率苯甲酸阿格列汀的制备方法
CN114105889A (zh) * 2021-12-16 2022-03-01 山东创新药物研发有限公司 一种dpp-iv抑制剂关键中间体的制备方法及其应用

Also Published As

Publication number Publication date
EP2410855A4 (en) 2012-10-17
EP2410855A1 (en) 2012-02-01
JP2012521411A (ja) 2012-09-13
AU2010228902A1 (en) 2011-10-06
EP2410855B1 (en) 2016-06-01
WO2010109468A1 (en) 2010-09-30
US8841447B2 (en) 2014-09-23
MX2011010079A (es) 2011-10-10
CA2755561A1 (en) 2010-09-30
BRPI1013561A8 (pt) 2015-09-22
BRPI1013561A2 (pt) 2015-08-25
US20120029000A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
CN102361557A (zh) 制备阿格列汀的方法
CN114008033B (zh) 胰高血糖素样肽1受体激动剂
CN107849037B (zh) 用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物
US9006454B2 (en) Dihydroorotate dehydrogenase inhibitors
KR101368988B1 (ko) 디펩티딜 펩티다제 억제제
US10662187B2 (en) Bruton's tyrosine kinase inhibitors
US20210253554A1 (en) Sulfone pyridine alkyl amide-substituted heteroaryl compounds
US20080234277A1 (en) Novel aza-pyridopyrimidinone derivatives
CN102140090A (zh) 二肽基肽酶抑制剂
CA2890981A1 (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses
CZ20011760A3 (cs) Pyrrolidinové deriváty jako antagonisty CCR-3 receptorů
WO2001027105A1 (en) Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof
KR20150092279A (ko) 암의 치료를 위한 신규한 2-고리 페닐-피리딘/피라진
ES2218439T3 (es) Indoloquinazolinonas.
WO2014154723A1 (en) Novel pyrrole derivatives for the treatment of cancer
JP7664642B2 (ja) 化合物およびｍｉｆ阻害剤としての用途
EP2903979A1 (en) Novel compounds, their preparation and their uses
US12391667B2 (en) N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases
CN109134481B (zh) 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
JP2011111433A (ja) ウレイド構造を有するウラシル化合物又はその塩
WO2008024784A1 (en) Alkylsulfonamide-substituted triazoles as matrix metalloprotease inhibitors
CA2554705A1 (en) Alpha-4 integrin mediated cell adhesion inhibitors for the treatment or prevention of inflammatory diseases
WO2018223122A1 (en) Hdac3-selective inhibitors
HK1165216A (en) Process for the preparation of alogliptin
US20170275327A1 (en) Substituted phosphoramidate compounds and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1165216

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120222

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1165216

Country of ref document: HK